Skip to Main Content

Author Details

Christoph Driessen
Cantonal Hospital St. Gallen
1994
133
47
PMIDPaper TitleJournal TitlePublished Year
36898749Acupuncture in chemotherapy-induced dysgeusia (AcuDysg): study protocol of a randomised controlled trial.BMJ Open2023
37410944Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.Swiss Med Wkly2023
37142661Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).Leukemia2023
37269857Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.Lancet Oncol2023
36693381Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.Med2023
36932175The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.Sci Rep2023
36635391Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.Leukemia2023
35269460Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.Cells2022
35840578The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.Nat Commun2022
35574642Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting.Hematol Oncol2022
35853457Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.Cell Chem Biol2022
35692781Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.Front Oncol2022
36225622Mutant <i>TP53</i> driving the Warburg Effect in Mantle Cell lymphoma.Clin Case Rep2022
32814840Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.Leukemia2021
33662288Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.Lancet Oncol2021
34858733Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.Oncoimmunology2021
34520219Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.J Clin Oncol2021
34756169COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network.Lancet Haematol2021
34631086Complete hematological and major molecular response through treatment with low-dose Interferon alpha 2a in high-risk polycythemia vera patient: a case report.Clin Case Rep2021
34478517Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma.Blood Adv2021
34158378Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.Cancer Res2021
34136753Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells.Hemasphere2021
33422770Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs.Leuk Res2021
32198923Impaired proteolysis by SPPL2a causes CD74 fragment accumulation that can be recognized by anti-CD74 autoantibodies in human ankylosing spondylitis.Eur J Immunol2020
30529903Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.Eur J Cancer2019
31698452Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.Blood Adv2019
31851164HIV protease inhibitors for the treatment of multiple myeloma.Clin Adv Hematol Oncol2019
30026573Spectrum and functional validation of PSMB5 mutations in multiple myeloma.Leukemia2019
31455773Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).Blood Cancer J2019
30954557Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.Biochim Biophys Acta Mol Basis Dis2019
30808934Management of cardiovascular risk in patients with multiple myeloma.Blood Cancer J2019
30943308Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.Swiss Med Wkly2019
31032109Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma.J Gastrointest Oncol2019
30792209A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.Haematologica2019
31021392Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.JAMA Oncol2019
30781685Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.Cancers (Basel)2019
30684020Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer.Cancer Chemother Pharmacol2019
30657666Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits.J Med Chem2019
30612952Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.Cell Chem Biol2019
28676669Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.Leukemia2018
30237154Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.Blood2018
30074631Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab.Hematol Oncol2018
30171031European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.Haematologica2018
30266819An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.Blood Adv2018
29720735Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.Leukemia2018
29161753Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.BJU Int2018
27983764Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup> -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Br J Haematol2017
29211715Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.Nature2017
29251284Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.Leukemia2017
28753594The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.Blood Cancer J2017
  • 1 - 50 of 133

Recommended Authors

Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 0
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Career Start Year 2012
Number of shared co-authors 0
John R Mills
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 0
Dhiraj Kumar
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 2
Aleksandra A Pandyra
Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf
Career Start Year 2003
Number of shared co-authors 0
Rajesh K Soni
Herbert Irving Comprehensive Cancer Center, Columbia University
Career Start Year 2002
Number of shared co-authors 0
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 0
Cristina C Clement
Englander Institute for Precision Medicine
Career Start Year 2001
Number of shared co-authors 1
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Sunil K Joshi
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 0
David M Weinstock
Merck & Co.
Career Start Year 1998
Number of shared co-authors 2
Eric Tse
School of Clinical Medicine, University of Hong Kong
Career Start Year 1997
Number of shared co-authors 2
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Zhiqiang An
Zhengzhou University
Career Start Year 1992
Number of shared co-authors 0
Ricky W Johnstone
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 0
Suzanne Trudel
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1990
Number of shared co-authors 1
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 1
Laura Santambrogio
Weill Cornell School of Medicine
Career Start Year 1988
Number of shared co-authors 2
Antony Rosen
Johns Hopkins University
Career Start Year 1988
Number of shared co-authors 0
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 0
Garry P Nolan
Stanford University School of Medicine
Career Start Year 1985
Number of shared co-authors 1
Thomas Decker
University of Vienna
Career Start Year 1985
Number of shared co-authors 1
Phuong Nguyen
Hoag Memorial Hospital Presbyterian
Career Start Year 1983
Number of shared co-authors 1
Patrick Auberger
Universite Cote d'Azur, INSERM U5
Career Start Year 1982
Number of shared co-authors 3
Paul Brent Ferrell
Vanderbilt University
Career Start Year 1981
Number of shared co-authors 0
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 1979
Number of shared co-authors 0
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 0
Ludwig Wagner
Child and Family Research Institute, University of British Columbia
Career Start Year 1979
Number of shared co-authors 1
Judy Lieberman
Boston Children's Hospital
Career Start Year 1978
Number of shared co-authors 0
Hiroshi Handa
Center for Future Medical Research, Tokyo Medical University
Career Start Year 1975
Number of shared co-authors 0

Collaborators

Arun P Wiita
University of California San Francisco
Co-authored papers 4
Bernhard O Boehm
Co-authored papers 4
Huib Ovaa
Leiden University Medical Center
Co-authored papers 3
Ian D Ferguson
Yale University School of Medicine
Co-authored papers 3
Yu-Hsiu Lin
University of California san francisco
Co-authored papers 3
Peter Leif Bergsagel
Co-authored papers 2
Anna Tramontano
Sapienza University of Rome
Co-authored papers 2
Margarette C Mariano
Albert Einstein College of Medicine
Co-authored papers 2
Stefan Aebi
University of Bern
Co-authored papers 2
Daniel D'Andrea
Nottingham Trent University
Co-authored papers 2
Janet L Anderl
Onyx Pharmaceuticals, Inc.
Co-authored papers 1
Lawrence H Boise
Winship Cancer Institute, Emory University
Co-authored papers 1
Reinhard Dummer
University Hospital Zurich
Co-authored papers 1
Ewa Koscielniak
Co-authored papers 1
Roland Beckmann
University of Munich
Co-authored papers 1
Jason E Gestwicki
Institute for Neurodegenerative Diseases, University of California San Francisco
Co-authored papers 1
Jing Tang
University of Helsinki
Co-authored papers 1
R Dyche Mullins
University of California San Francisco, USA Howard Hughes Medical Institute
Co-authored papers 1
Scott R VandenBerg
University of California san francisco
Co-authored papers 1
Alexander Keith Stewart
Co-authored papers 1
Hao Shao
Department of Pharmaceutical Chemistry, University of California San Francisco
Co-authored papers 1
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
Makeba Marcoulis
University of California san francisco
Co-authored papers 1
Sundararajan Vincent Rajkumar
Co-authored papers 1
Andr?? S Bachmann
College of Human Medicine, Michigan State University
Co-authored papers 1
Stefan Kubicek
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
Co-authored papers 1
Raffael Kurek
Oncology Clinical Development
Co-authored papers 1
Casey S Greene
Co-authored papers 1
Karen Byth
Westmead Hospital
Co-authored papers 1
Niels Weinhold
Co-authored papers 1
Release 1.2